Pneumococcal Vaccines: PCV13, PCV20, PCV21, and PPSV23

  1. Conjugate vs. Polysaccharide Vaccines
  2. PCV7 to PCV13: The Conjugate Journey
  3. PCV15, PCV20, and PCV21: Current Adult Options
  4. PCV for Infants: The 4-Dose Series
  5. PPSV23 (Pneumovax 23): When It Still Fits
  6. Who Needs Pneumococcal Vaccination
  7. Vaccine-Serotype Replacement: A Critical Limitation
  8. Herd Immunity and Its Impact on Adults
  9. Key Research Papers
  10. PubMed Topic Searches
  11. Connections
  12. Featured Videos

Conjugate vs. Polysaccharide Vaccines — Why the Type of Vaccine Matters

Not all pneumococcal vaccines work the same way inside your immune system, and that difference is the key to understanding why you might need more than one type, or why children need a different formulation than adults.

The outer coat of Streptococcus pneumoniae is made of polysaccharide — a sugar-like chain molecule. Early vaccines simply packaged these polysaccharides from multiple serotypes (strains) into a single shot, expecting your immune system to recognize them and build antibodies. This works reasonably well in healthy adults, but the response has a fundamental flaw: it skips immunological memory.

Plain polysaccharide vaccines activate B cells directly, without involving T-helper cells. That type of immune response — called T-independent — produces antibodies that circulate for a few months, then fade. Worse, if you get a booster shot years later, your immune system does not mount a stronger response. It behaves as though it never saw the antigen before. This is not how memory is supposed to work. In children under two years old, the T-independent pathway barely functions at all, which means plain polysaccharide vaccines are almost completely ineffective in infants.

Conjugate vaccines solve this problem by chemically linking the polysaccharide to a carrier protein — most commonly CRM197, a non-toxic mutant form of diphtheria toxin. When your immune system sees the combination, it recruits T-helper cells to assist. T cells are the architects of immunological memory. The result is:

That last point — reducing carriage — turned out to be enormously important. When vaccinated children stop carrying pneumococcal bacteria in their throats, they stop spreading those serotypes to the elderly people around them. This is how childhood vaccination ended up protecting grandparents who had never received any pneumococcal vaccine themselves.

Back to Table of Contents

PCV7 to PCV13 — The Conjugate Vaccine Journey

The story of pneumococcal conjugate vaccines in the United States is one of the clearest success stories in modern public health — and one of the clearest demonstrations of how rapidly bacteria can adapt when you eliminate their competition.

PCV7 (Prevnar), approved in 2000, covered seven pneumococcal serotypes: 4, 6B, 9V, 14, 18C, 19F, and 23F. At the time, those seven serotypes caused roughly 80% of invasive pneumococcal disease in American children. Within five years of widespread use:

But the bacteria did not disappear. Serotypes not covered by PCV7 began filling the space left behind. Most consequentially, serotype 19A surged. By the mid-2000s, 19A had become the leading cause of invasive pneumococcal disease in US children and a major source of antibiotic resistance, because many 19A strains are multidrug-resistant.

PCV13 (Prevnar 13), approved in 2010, extended coverage to 13 serotypes by adding 1, 3, 5, 6A, 7F, and 19A to the original seven. Serotype 19A was specifically included to address the post-PCV7 surge. The results were again impressive:

PCV13 remained the standard pediatric and adult conjugate vaccine for over a decade. In adults aged 65 and older, it was recommended in combination with PPSV23 until newer vaccines arrived.

Back to Table of Contents

PCV15 and PCV20 — Current Adult Options

By the late 2010s, surveillance data made clear that the serotypes not covered by PCV13 were responsible for a growing share of invasive pneumococcal disease in adults. Vaccine manufacturers responded with broader-coverage formulations.

PCV15 (Vaxneuvance, approved 2021) adds serotypes 22F and 33F to the PCV13 lineup. Both had become important causes of adult invasive disease in the years following PCV13 introduction. PCV15 uses the same conjugation approach as earlier vaccines.

PCV20 (Prevnar 20, approved 2021) takes a larger leap, adding seven new serotypes to the PCV13 base: 8, 10A, 11A, 12F, 15B, 22F, and 33F. Together, these 20 serotypes are estimated to cover approximately 85–90% of remaining invasive pneumococcal disease in US adults.

In 2021, the Advisory Committee on Immunization Practices (ACIP) issued updated recommendations for adults aged 65 and older:

PCV21 (Apexxnar in some countries, Prevenar 21 in others) was approved in Canada and several European countries in 2023–2024, adding serotypes beyond PCV20's coverage. It targets additional non-vaccine serotypes that surveillance has flagged as emerging in post-PCV13 and post-PCV20 populations. PCV21 approval processes in the US were ongoing as of mid-2026; check current CDC guidance for the latest status.

The trajectory is unmistakable: each generation of conjugate vaccine covers more serotypes, driven by bacterial ecology adapting around previous vaccines. Whether you need the latest and broadest formulation depends on your age, immune status, and what vaccines you have already received.

Back to Table of Contents

PCV for Infants — The 4-Dose Series

For healthy infants in the United States, pneumococcal conjugate vaccination follows a standard 4-dose schedule that has been part of the routine childhood immunization program since 2000. The schedule is designed to build immunity during the period of life when invasive pneumococcal disease — especially meningitis and bloodstream infections — is most dangerous.

Standard schedule:

The first three doses prime the immune system; the fourth dose, given after the first birthday, is a booster that dramatically strengthens and consolidates memory. Skipping or delaying the fourth dose significantly reduces long-term protection.

How well does it work?

What if doses were missed or delayed? A catch-up schedule exists. A child who started late or fell behind can still complete the series, though the exact schedule depends on the child's current age and how many doses have already been given. Your pediatrician or the CDC's catch-up schedule tool can walk you through it. The important thing is not to assume that missing the standard timing means skipping vaccination — partial protection is still meaningful, and completing the series remains worthwhile.

Children with high-risk conditions (asplenia, HIV, cochlear implants, CSF leaks, immunosuppression) may receive additional doses beyond the standard 4-dose series. Your child's doctor will recommend the appropriate schedule.

Back to Table of Contents

PPSV23 (Pneumovax 23) — When It Still Fits

PPSV23 is the plain polysaccharide vaccine — the older type that does not generate immunological memory. It covers 23 pneumococcal serotypes, more than any current conjugate vaccine, which was once its main selling point. Understanding where it still fits requires knowing both its strengths and its limitations.

What PPSV23 does well:

What PPSV23 does not do well:

Current role for PPSV23: With the approval of PCV20, ACIP no longer recommends PPSV23 as the primary adult pneumococcal vaccine for most people. However, it still has a role in specific situations:

For most people starting pneumococcal vaccination today, PCV20 alone is the simplest and preferred path. PPSV23 mainly matters if you have a partial vaccination history from an earlier era of recommendations.

Back to Table of Contents

Who Needs Pneumococcal Vaccination

Pneumococcal vaccination is recommended for a wide range of people — not just the elderly. Here is a plain-language breakdown of who should be vaccinated and with what.

All adults aged 65 and older: Receive PCV20 (preferred, one-time shot) OR PCV15 followed by PPSV23 at least one year later. This is a universal recommendation regardless of health status. If you have already received pneumococcal vaccination earlier in life, ask your doctor whether you need an update based on what you received and when.

Adults under 65 with high-risk medical conditions — PCV20 recommended:

Adults under 65 with conditions that severely compromise immunity — highest priority:

Children: Follow the routine 4-dose PCV schedule (2, 4, 6, and 12–15 months). Children with high-risk conditions receive additional doses. Children with asplenia or immunocompromise may also receive PPSV23 starting at age 2, at least 8 weeks after completing the PCV series.

If you are unsure whether you have been vaccinated, ask your doctor to check your immunization records. In many states, vaccination records are available through online registries. There is no harm in receiving PCV20 if your previous vaccination history is uncertain — starting fresh is better than going unprotected.

Back to Table of Contents

Vaccine-Serotype Replacement — A Critical Limitation

There is a fundamental ecological reality about pneumococcal vaccination that every informed patient should understand: eliminating vaccine serotypes from the human population opens a niche that other serotypes rapidly fill. This is called serotype replacement, and it is the main reason pneumococcal vaccines keep requiring updates.

Think of it this way. S. pneumoniae normally colonizes the back of the nose and throat in about 10–20% of healthy adults and up to 50–60% of young children at any given time. Different serotypes compete with each other for this colonization niche. When a vaccine eliminates vaccine-covered serotypes from carriage, the ecological space does not stay empty — non-vaccine serotypes expand to occupy it.

What happened after PCV7 (2000–2010):

What is happening after PCV13 (2010–present):

What this means for you: No pneumococcal vaccine will permanently eliminate the disease. Ongoing surveillance by the CDC, WHO, and national health agencies tracks serotype trends so that vaccine formulations can be updated. The practical implication is that vaccine recommendations will continue to evolve. A vaccine you received 10 years ago may cover different serotypes than today's recommended formulations. Staying current with updated recommendations is not redundancy — it is how the public health system responds to a moving target.

Surveillance is also why researchers are actively working on protein-based vaccines that would target conserved surface proteins present on all pneumococcal serotypes, bypassing the serotype-replacement problem entirely. These universal pneumococcal vaccines remain in clinical trials as of 2025.

Back to Table of Contents

Herd Immunity and the Impact on Adults

One of the most striking findings from the pneumococcal vaccination program is how dramatically vaccinating children protected adults who had never received any pneumococcal vaccine. This herd immunity effect was documented in real time as PCV7 and PCV13 rolled out across the United States, and it revealed something important about how S. pneumoniae spreads.

Children are the key reservoir. Young children carry pneumococcal bacteria in their throats at high rates and transmit them efficiently to household contacts, including elderly grandparents, immunocompromised relatives, and others who spend time with them. Before conjugate vaccines, the pediatric population was effectively a constant pneumococcal incubator — seeding the surrounding adult population with circulating serotypes.

When conjugate vaccination reduced nasopharyngeal carriage of vaccine serotypes in children, transmission to adults dropped accordingly. The results in adults were striking:

This herd protection effect has a practical implication: high childhood vaccination coverage is not just good for children — it is a form of elder care. Communities with higher rates of childhood immunization see lower rates of adult invasive disease. Conversely, declines in childhood vaccination rates, whether from logistics, vaccine hesitancy, or access barriers, erode this community-level protection.

Direct vaccination of adults still matters — herd protection does not eliminate adult risk, and adults with high-risk conditions cannot rely on herd immunity alone. But the herd effect illustrates why pneumococcal vaccination policy is designed as a two-pronged strategy: universal childhood immunization provides community-level pressure on circulating serotypes, while adult vaccination fills in the gaps and directly protects those with weakened defenses.

Back to Table of Contents

Key Research Papers

The following studies are foundational to our understanding of pneumococcal vaccines, serotype dynamics, and vaccination outcomes.

PubMed Topic Searches

These searches retrieve current and ongoing research in the literature:

  1. Pneumococcal conjugate vaccine — adults
  2. PCV20 efficacy and immunogenicity
  3. Sequential PPSV23 and PCV13 vaccination
  4. Serotype replacement after pneumococcal vaccination
  5. Pneumococcal herd immunity from childhood vaccination
  6. Pneumococcal vaccination in asplenia and immunocompromised patients
  7. Nasopharyngeal carriage and conjugate vaccines

Connections

Back to Table of Contents